RxDoctor Payments Data

Mary Holley, MD

Gynecology · Guntersville, ALNPI 1528338126

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $267 of the $377 with a category attached, or 70.8%. 11 manufacturers reported payments, led by Astellas Pharma US Inc at 24.4% of the total. Reporting peaked in 2022 at $165 and has fallen 60.8% since, to $65 in 2024.

$377in general payments, 2019–2025

Across 19 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$92
  • BD$59
  • Medtronic$54
  • AMAG Pharmaceuticals, Inc.$38
  • AbbVie$34
  • Pfizer$27
  • plus $72 from 5 others

What the payments were for

  • Food & beverage$26771%
  • Education$11029%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$377 in reported general payments places this provider in the 60th percentile of 51 gynecology providers in Alabama.

See all gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$42,688
Medicare patients
161
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron55$40,786
Estradiol322$13,923
PremarinEstrogens, Conjugated11$5,953
Fluconazole188$2,440
Clobetasol Propionate57$1,963
ValacyclovirValacyclovir Hcl31$1,841
Raloxifene Hcl26$1,827
Medroxyprogesterone Acetate82$1,406
Estradiol (Twice Weekly)Estradiol20$1,324
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet22$1,299
Tolterodine Tartrate ErTolterodine Tartrate13$1,062
Norethindrone Acetate18$899
Betamethasone Dipropionate22$841
ProgesteroneProgesterone, Micronized13$836
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip52$792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$92$40,78655 claims
PfizerPremarin$27$5,95311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 51 gynecology providers in Alabama.

Other gynecology in Guntersville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →